These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31728884)

  • 1. Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy.
    Alcaide-Leon P; Luks TL; Lafontaine M; Lupo JM; Okada H; Clarke JL; Villanueva-Meyer JE
    J Neurooncol; 2020 Jan; 146(1):71-78. PubMed ID: 31728884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
    Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis.
    Song YS; Choi SH; Park CK; Yi KS; Lee WJ; Yun TJ; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Jahng GH; Chang KH
    Korean J Radiol; 2013; 14(4):662-72. PubMed ID: 23901325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
    Rulseh AM; Vymazal J
    J Neurooncol; 2020 Jan; 146(1):157-162. PubMed ID: 31797235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
    Yoo RE; Choi SH; Kim TM; Lee SH; Park CK; Park SH; Kim IH; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2015 Oct; 36(10):1846-52. PubMed ID: 26294653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma.
    Deike K; Wiestler B; Graf M; Reimer C; Floca RO; Bäumer P; Kickingereder P; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    J Neurooncol; 2016 Feb; 126(3):463-72. PubMed ID: 26518541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility-weighted imaging provides complementary value to diffusion-weighted imaging in the differentiation between pyogenic brain abscesses, necrotic glioblastomas, and necrotic metastatic brain tumors.
    Lai PH; Chung HW; Chang HC; Fu JH; Wang PC; Hsu SH; Hsu SS; Lin HS; Chuang TC
    Eur J Radiol; 2019 Aug; 117():56-61. PubMed ID: 31307653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy.
    Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Liau LM; Pope WB
    Neuro Oncol; 2013 Mar; 15(3):382-90. PubMed ID: 23275575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
    Kim BR; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
    PLoS One; 2016; 11(11):e0166096. PubMed ID: 27835666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.
    Nguyen HS; Milbach N; Hurrell SL; Cochran E; Connelly J; Bovi JA; Schultz CJ; Mueller WM; Rand SD; Schmainda KM; LaViolette PS
    AJNR Am J Neuroradiol; 2016 Dec; 37(12):2201-2208. PubMed ID: 27492073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
    Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
    Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apparent diffusion coefficient parametric response mapping MRI for follow-up of glioblastoma.
    Yoon RG; Kim HS; Kim DY; Hong GS; Kim SJ
    Eur Radiol; 2016 Apr; 26(4):1037-47. PubMed ID: 26159871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
    Lee WJ; Choi SH; Park CK; Yi KS; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH
    Acad Radiol; 2012 Nov; 19(11):1353-61. PubMed ID: 22884399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
    Zolal A; Juratli TA; Linn J; Podlesek D; Sitoci Ficici KH; Kitzler HH; Schackert G; Sobottka SB; Rieger B; Krex D
    J Neurooncol; 2016 May; 127(3):551-7. PubMed ID: 26830088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
    Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
    Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
    Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
    Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of peritumoral minimum apparent diffusion coefficient for differentiation of glioblastoma multiforme from solitary metastatic lesions.
    Lee EJ; terBrugge K; Mikulis D; Choi DS; Bae JM; Lee SK; Moon SY
    AJR Am J Roentgenol; 2011 Jan; 196(1):71-6. PubMed ID: 21178049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
    Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
    Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.